• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 1
  3. Author

Online ISSN: 2515-8260

Volume9, Issue1

Efficacy of topical 0.05% cyclosporine in Vernalkeratoconjunctivitis

    Erum Waris Khateeb, Tania Sadiq, Sheikh Sajjad

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 1, Pages 118-122

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Vernal keratoconjunctivitis (VKC) is a chronic recurrent non-infectious
allergic disease that generally affects children and young adults. The present study was
conducted to assess efficacy of topical 0.05% cyclosporine in Vernalkeratoconjunctivitis.
Materials & Methods:86 patients diagnosed with Vernalkeratoconjunctivitis (VKC) of both
genderswere enrolled. All were prescribed topical 0.05% cyclosporine 4 times a day.
Patients underwent complete ophthalmic examination and symptoms and signs and
intraocular pressure using non contact tonometer. The patients were evaluated at weeks 4,
8 and 12 after the initiation of therapy. Symptoms and signs before and after treatment,
during the four-week intervals, were recorded and scores between 0 and 3 were assigned.
Results: Out of 86 patients, males were 56 and females were 30. Median of symptoms score
at baseline was 11, at 4 weeks were 4, at 8 weeks were 5 and at 12 weeks were 4. Sign score
at baseline was 6, at 4 weeks were 4, at 8 weeks were 3 and at 12 weeks were 3. The
difference was significant (P< 0.05).
Conclusion: Topical cyclosporine 0.05% help to reduce corticosteroid usage, is an effective
and safe alternative for the treatment of resistant VKC.
Keywords:
    Cyclosporine Eye Vernal keratoconjunctivitis
  • PDF (248 K)
  • XML
(2022). Efficacy of topical 0.05% cyclosporine in Vernalkeratoconjunctivitis. European Journal of Molecular & Clinical Medicine, 9(1), 118-122.
Erum Waris Khateeb, Tania Sadiq, Sheikh Sajjad. "Efficacy of topical 0.05% cyclosporine in Vernalkeratoconjunctivitis". European Journal of Molecular & Clinical Medicine, 9, 1, 2022, 118-122.
(2022). 'Efficacy of topical 0.05% cyclosporine in Vernalkeratoconjunctivitis', European Journal of Molecular & Clinical Medicine, 9(1), pp. 118-122.
Efficacy of topical 0.05% cyclosporine in Vernalkeratoconjunctivitis. European Journal of Molecular & Clinical Medicine, 2022; 9(1): 118-122.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 156
  • PDF Download: 156
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus